BioSpace News Archive

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 40th Annual JP Morgan Healthcare Conference.

Azenta, Inc. (Nasdaq:AZTA) announced today that company management will participate in the 40th Annual J.P. Morgan Healthcare Conference.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), today announced FDA 510(k) clearance that expands on-label use of the FREEDOM60 Infusion System to two additional subcutaneous Ig (SCIg) medications, Cutaquig®, manufactured by Octapharma, and Xembify®, manufactured by Grifols.

The FDA, along with the CDC and our state and local partners, is working to investigate a multistate outbreak of Listeria monocytogenes infections.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, published its third annual Patient Access Philosophy Report.

Novavax, Inc. announced that the World Health Organization Strategic Advisory Group of Experts on Immunization has published its interim recommendations for use of NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant.

Cytonus Therapeutics Inc., a US-based biotechnology company developing an innovative drug-delivery platform technology called Cargocytes, today announced the publication of a peer reviewed research paper in the high impact journal, Nature Biomedical Engineering.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.

Allarity Therapeutics, Inc. announced the closing of its Recapitalization Share Exchange resulting in its initial public listing of 8,075,824 shares of its common stock and listing on the U.S Nasdaq Stock Market under the trading symbol “ALLR.”.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara’s proprietary biosimulation software, with more than 400 user licenses of Simcyp and Phoenix software.